Application Information: IL17 Receptor alpha antibody [8D15]

We recommend the following starting dilutions:
For WB: Use at a dilution of 1:500-1:1000.
For Neutralization:Recombinant Human (rh)IL 17 can induce GRO alpha secretion in the human K562 cancer cells in a dose dependent manner. GRO alpha secretion elicited by rhIL 17 can be neutralized by increasing concentrations of GTX52824. When 50ng/ml of rhIL-17 was used, the ED50 is typically at 500-2000 ng/mL.
Optimal dilutions should be determined experimentally by the end user.

Form Supplied

Liquid

Purification

The IgG fraction of culture supernatant was purified by Protein G affinity chromatography

Specifications: IL17 Receptor alpha antibody [8D15]

Full Name

interleukin 17 receptor A

Product Description

Mouse monoclonal antibody [8D15] to IL-17 R

Background

Interleukin 17A (IL17A)is a proinflammatory cytokine secreted by activated T-lymphocytes. It is a potent inducer of the maturation of CD34-positive hematopoietic precursors into neutrophils. The protein encoded by this gene (interleukin 17A receptor; IL17RA) is a ubiquitous type I membrane glycoprotein that binds with low affinity to interleukin 17A. Interleukin 17A and its receptor play a pathogenic role in many inflammatory and autoimmune diseases such as rheumatoid arthritis. Like other cytokine receptors, this receptor likely has a multimeric structure. [provided by RefSeq, Jul 2008]